Wellspring Financial Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 287.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,333 shares of the company’s stock after acquiring an additional 1,731 shares during the quarter. Wellspring Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $2,509,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Brighton Jones LLC boosted its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its position in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the period. Schnieders Capital Management LLC. boosted its position in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares during the period. Flow Traders U.S. LLC purchased a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC purchased a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $749,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on LLY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Rothschild & Co Redburn raised their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Finally, Leerink Partners set a $1,119.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,227.74.
Eli Lilly and Company Price Performance
Eli Lilly and Company stock opened at $1,138.78 on Thursday. The stock has a market cap of $1.07 trillion, a P/E ratio of 40.45, a price-to-earnings-growth ratio of 1.25 and a beta of 0.53. The company has a fifty day simple moving average of $989.96 and a 200-day simple moving average of $1,015.14. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,182.73. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.
Key Stories Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: FDA approval for a longer-dated EBGLYSS maintenance regimen boosts Lilly’s dermatology franchise and broadens growth beyond obesity and diabetes, while also making the therapy easier for patients to stay on. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
- Positive Sentiment: Analysts have nudged up FY2026 EPS estimates, reinforcing confidence that Lilly’s earnings momentum remains strong and above consensus expectations. MarketBeat stock background
- Positive Sentiment: Recent reports highlighted strong clinical and commercial momentum across Lilly’s obesity pipeline, including Foundayo and retatrutide, which supports the company’s leadership in GLP-1 and incretin drugs. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
- Positive Sentiment: Jefferies raised its price target and reiterated a Buy rating, adding to the bullish analyst tone around Lilly’s pipeline and valuation. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
- Neutral Sentiment: Lilly also announced an Alzheimer’s licensing deal with AlzeCure that expands its neuroscience pipeline, but the financial impact is still early-stage and tied to future milestones. Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
- Negative Sentiment: Reuters reported some U.S. employers may start dropping coverage for GLP-1 weight-loss drugs in 2027 as usage rises, which could eventually pressure demand for Zepbound and other obesity treatments. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
